A clinical trial investigating the use of puberty blockers in children experiencing gender dysphoria has been paused by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The decision, announced Friday, stems from concerns regarding the wellbeing of potential participants and the potential for “long-term biological harms,” prompting a review of the trial’s age eligibility criteria.
The trial, known as Pathways, was designed to gather much-needed evidence on the effects of puberty blockers – medications that temporarily suppress the physical changes of puberty – in young people. It followed recommendations from the independent Cass Review, which highlighted a “weak evidence base” for the benefits of these treatments and called for more rigorous research. The pause underscores the complex ethical and medical considerations surrounding gender-affirming care for minors.
The MHRA has specifically raised concerns about the initial proposed age range for participants, which included children as young as 10 and 11. The agency is now suggesting a minimum age of 14, advocating for a “graded/stepwise approach” to enrollment. In a letter to King’s College London, the trial sponsor, the MHRA stated that “potentially significant and, as yet, unquantified risk of long-term biological harms is present to participants” and that biological safety has not been definitively demonstrated in younger cohorts. A copy of the letter is available on the government website.
Cass Review and the Need for Evidence
The Pathways trial was conceived as a direct response to the findings of Dr. Hilary Cass’s review of gender identity services for children and young people in England. The Guardian reported that the Cass Review concluded the existing research on puberty blockers was of “poor” quality. Dr. Cass herself acknowledged the lack of robust evidence but emphasized the importance of a trial to better understand the potential benefits and risks, stating that a trial was “the only way forward to make sense of this.”
NHS England subsequently announced that puberty blockers would no longer be routinely prescribed to children with gender dysphoria, restricting their use to research settings. This decision further emphasized the need for a well-designed and carefully monitored trial like Pathways.
Concerns Raised by the MHRA
The MHRA’s intervention focuses on ensuring the safety and wellbeing of the young people who would participate in the study. Beyond the age limit, the agency has requested more detailed monitoring of bone density and a more rigorous consent process. The Department of Health and Social Care (DHSC) confirmed that discussions between the MHRA and King’s College London will start next week to address these concerns. The trial will remain paused until these issues are resolved.
A spokesperson for the DHSC stated on Friday, “We have always been clear about the red lines regarding this trial – ensuring the safety and wellbeing of the children and young people involved and always being led by the clinical evidence.” They added that the trial will only proceed if expert scientific and clinical advice confirms it is both safe and necessary.
King’s College London Responds
King’s College London, the sponsor of the Pathways trial, affirmed its commitment to the wellbeing of young people and their families. A spokesperson stated that the institution will continue to perform with the MHRA to address the agency’s concerns, emphasizing the trial’s “scientific rigour” and its potential to build an evidence base for better-informed clinical decisions. The trial had initially planned to recruit approximately 226 young people over three years.
Professor Sir Jonathan Montgomery, professor of health care law at University College London, described the pause as a positive sign, stating, “This pause shows the regulatory process working properly and in the interests of participants.” He clarified that the MHRA’s concerns are focused on strengthening the trial protocol, not halting it altogether.
The pause in the Pathways trial highlights the ongoing debate and careful scrutiny surrounding the use of puberty blockers in young people experiencing gender dysphoria. The focus remains on gathering robust evidence to inform clinical practice and ensure the best possible care for this vulnerable population. What comes next will depend on the outcome of the discussions between the MHRA and King’s College London, and whether the trial protocol can be adjusted to address the agency’s safety concerns.
This is a developing story, and we will continue to provide updates as they become available. Please share your thoughts and engage in respectful discussion in the comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
